- Switzerland
- /
- Medical Equipment
- /
- SWX:METN
Metall Zug Full Year 2023 Earnings: Revenues In Line With Expectations
Metall Zug (VTX:METN) Full Year 2023 Results
Key Financial Results
- Revenue: CHF494.7m (down 23% from FY 2022).
- Net income: CHF22.2m (down 83% from FY 2022).
- Profit margin: 4.5% (down from 20% in FY 2022). The decrease in margin was driven by lower revenue.
All figures shown in the chart above are for the trailing 12 month (TTM) period
Metall Zug Meets Expectations
Revenue was in line with analyst estimates.
Looking ahead, revenue is forecast to grow 4.7% p.a. on average during the next 2 years, compared to a 8.0% growth forecast for the Medical Equipment industry in Switzerland.
Performance of the Swiss Medical Equipment industry.
The company's shares are down 5.5% from a week ago.
Risk Analysis
Be aware that Metall Zug is showing 2 warning signs in our investment analysis that you should know about...
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About SWX:METN
Metall Zug
Through its subsidiaries, engages in the medical devices, infection control, technology cluster and infrastructure, and other businesses in Switzerland, rest of Europe, the Americas, the Asia Pacific, and internationally.
Excellent balance sheet and fair value.